Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Eli Lilly and Company
Institut Claudius Regaud
City of Hope Medical Center
M.D. Anderson Cancer Center
Eli Lilly and Company
University of Arizona
Sanofi
Sanofi
Exelixis
Peking Union Medical College Hospital
Jonsson Comprehensive Cancer Center
University of Pennsylvania
University Medical Center Groningen
Hoffmann-La Roche
Instituto do Cancer do Estado de São Paulo
Sanofi
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
University Hospital, Basel, Switzerland
Mayo Clinic
First Affiliated Hospital of Fujian Medical University
NantCell, Inc.
Turning Point Therapeutics, Inc.
M.D. Anderson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
National Cancer Institute (NCI)
TYK Medicines, Inc
Hoffmann-La Roche
National Cancer Institute (NCI)
University College, London
Boston Pharmaceuticals
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Shouyao Holdings (Beijing) Co. LTD
Icahn School of Medicine at Mount Sinai
Nantes University Hospital
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
University Hospital, Basel, Switzerland
Columbia University
H. Lee Moffitt Cancer Center and Research Institute
Exelixis
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
Azienda Ospedaliero, Universitaria Pisana
National Cancer Institute (NCI)